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ABSTRACT 
Value of biotechnology firms relies upon the complex interplay between human capital and IP 
assets, where, human capital translates the market potential of IP asset to the true market value. 
This study aims to introduce the human capital of biotech firms into already existing valuation 
models in form of human resource factor (hrf). Built as an extension on available literature, a 
theoretical linear model consisting six parameters, viz.; breed of managers, star scientists, 
knowledge continuity, human resource interaction and CEO effect, was developed to estimate 
the human capital. The human capital determines the translational efficiency of firm’s potential 
to market values. In order to evaluate the relevance of the model, a pilot scale study of five 
biotech companies, based in Hamar and Oslo, was carried out through the use of questionnaire-
based interview. Findings from interview showed that Company B has highest hrf value, while 
Company D has the lowest. Finally, implementing a scorecard based on this linear model could 
prove to be fruitful in enhancing firm’s market value. 
Keywords: human resource factor, translational efficiency, valuation.  
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1 INTRODUCTION 
Field of biotechnology was emanated with the main aim of enhancing human life through 
research, development and commercialization. This industry involves capital-intensive research 
and development (R&D) programs where venture capital, public funding, private funding, 
government sources and grants are the sources of sustenance. However, these sources should be 
attracted through lucrative value proposition.  
Biotechnology institutions are often involved in technology transfer, fund raising, Initial Public 
Offering (IPO), licensing strategies and revenue generation, portfolio management, joint venture 
agreements, collaborative research, investment decisions, merger and acquisition as a part of 
their strategic steps to achieve the goals (Bogdan & Villiger, 2010). All these activities rely on 
the value of the company or a project. Arojarvi (2001) argues that the turbulence in the stock 
market around the globe is the outcome of the fact that no one knows the exact value of present 
day economy. This situation is more prominent in the field of biotech. Stock prices can fluctuate 
dramatically, in response to news developments particularly concerning failure or success of 
particular drug or product under trial. Investors must carefully consider a possible stock market 
reaction such as risk and reward associated with a particular product. They have few metrics to 
base their investment decision in biotech firms (Bogdan & Villiger, 2010). Thus, the investment 
in biotech firms is largely suited to risk tolerant investors (Maharaj, 2013). Therefore, valuation 
is a crucial financial issue for every biotech company.  
Biotech industries are characterized by certain industry factors which are unique to them, such 
as, companies’ product development pipeline, capital burn rate (level and rate of expenditure 
required for R&D), survival index (measurement of the relationship between net cash in hand 
and burn rate), uncertainty etc (Bratic, Tilton, & Balakrishnan, 1997). These factors play a major 
role in valuation of biotechnology companies. However, fewer studies have been carried out in 
biotech valuations. There have been some efforts to incorporate managerial flexibility in 
valuation models but human resource component has been rarely captured by already existing 
models. Thus, attractive and widely acceptable valuation model that incorporates the human 
capital of a firm is a present day essence in the field of biotechnology. This study is an effort 
towards introducing human capital in life science valuation models. 
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1.1 Valuation in biotechnology 
Financial management is a major issue on every company.  Small biotech companies need cash 
for their growth and development, and their existence is jeopardized if the management team 
cannot be prudent enough to muster investment sources. Furthermore, during licensing activities, 
mergers and acquisitions, it is important to demonstrate the valuation work to other concerned 
stakeholders and partners (Lalandes, 2012). Valuation should reflect a sum of the total assets that 
may be tangible or intangible. Mostly, the value of Biotech Company relies on their intangible 
assets they possess. A company value lies in its potential to generate a stream of profits in the 
future through proper utilization of its intangible assets. Thus, the intangible assets play an 
important role in valuation of biotechnology sector. 
Valuation theoretically guides the investment choice and profitability. In biotechnology, 
valuation is the sum of existing company value, market position and opportunity, and future 
products based on present intangible assets. Valuing the present intangible assets based on their 
future potential and market opportunities is a major challenge in biotechnology valuation. 
Furthermore, uncertainty in R&D outcomes along with future market unpredictability makes the 
task more arduous (Ljumović, Cvijanović, & Lazi, 2012). Jovanović, Matović, & Petrović (2011) 
emphasized on greater value of intangible assets in business activities and stated that the 
intangible assets share in business activities has risen from 5% in 1970s to 90% in 2004. Thus, 
business valuation has become more and more complex up to the present day with the increasing 
share of intangible assets. This complexity has entangled the biotechnology valuation more than 
any other sectors.  
In biotechnology sector, Discounted Cash Flow (DCF) and Real options are the two major 
quantitative valuation techniques (Bogdan & Villiger, 2010). DCF has been used for a long time 
as the major valuation techniques because of its simplicity in application. This trend could not 
continue to remain as a gold standard until present day business where greater value is applied in 
intangible assets, and there is more uncertainty associated with it. Furthermore, this valuation 
technique shows negative valuation for early stage developing companies. Real options valuation 
technique was developed to overcome the pitfalls associated with DCF. It is more complicated to 
apply, but it is considered to be a more flexible valuation technique. 
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1.2 Human capital in valuation 
Life cycle of life science companies, as shown by Collingham (2004) resembles a golden triangle 
of finance, intellectual property and management. Scientists with IP assets need complementary 
financial and commercial skills. On the other hand, an ideal management team may need better 
technologies and better scientists for commercial exploitation. According to Edvinsson & 
Malone (1999), the corporate value cannot be derived directly from any one of the components 
of intellectual capital (structural capital, relational capital and human capital) but it is an outcome 
of complex interplay between all these factors. The trilateral equilibrium is essential for proper 
translation of intellectual capital into corporate value. No matter how strong are two factors, if 
the remaining third is weak, the firm has no potential to translate its intellectual capital into 
actual market value. The biotech company valuation models such as DCF and real options 
models have well-incorporated relational capital and structural capital for their future value 
projection. However, they fail to incorporate the human capital and thus are unable to maintain 
the trilateral equilibrium. Thus, in the following sections, human capital in terms of human 
resource factor is considered to overcome the shortcomings of previous valuation models. 
1.3 Objectives of the study 
This study aims to provide a better tool for the biotech industry to estimate their market value 
through better understanding of translational efficiency of their existing human resources. Thus, 
introduction of the translational efficiency of human resources in terms of human resource factor 
in life science company valuation models is the general objective of this study. 
Specific objectives of the study are; 
 To explain the dynamics of product development pipelines in the biotech sector 
 To discuss and identify key value drivers in the biotech sectors 
 To provide a brief introduction on already existing valuation models in biotechnology 
 To analyze the shortcoming of  existing models 
 To introduce a new model for scoring the value of human capital in the biotechnology 
sector 
 To introduce human resource factor in existing models 
 To test the hypothesis with real life data in pilot scale 
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1.4 Rational of the study 
Valuation is an integral part of biotech product life cycle. In each stage of biotech company life 
cycle, such as, external fundraising, licensing out, mergers and acquisitions, during IPO plan, 
value of a company needs to be assessed. High attrition rate, high burn rate, lengthy timeline and 
highly regulated nature of biotech business add uniqueness and complexity in its valuation 
approaches. Despite these associated complexities, various models have been introduced for 
valuation. These efforts range from early 1880s practice of measurement of lab footage, counting 
the number scientists and PhD employed to highly theoretical nature of real option valuation 
models in 21
st
 century (Stewart, Allison, & Johnson, 2001).  
With the increasing importance of intangibles, value estimation based on the market potential of 
intellectual capital has also been taken into consideration. These estimations are based on 
structural component (relational and IP assets) of intellectual capital. The human resource 
component of intellectual capital has been missing or not properly explained in the existing 
literature related to biotech valuation models. Therefore, this research focuses on the analysis of 
appropriate human resource that can maintain trilateral equilibrium in the golden triangle of 
biotech life cycle as explained by (Collingham, 2004). Human capital with high translation 
efficiency can only create the market value of other intellectual capital (structural and relational) 
to its full potential. Thus, this study aims in incorporating the human capital as an essential 
component of biotech valuation model.  
1.5 Disposition 
This dissertation work is organized in different sections. Section 1 deals with an introduction on 
life science company valuation, role of human capital in firm’s value and the rationale behind 
this research that attempts to link the human capital with firm’s market value. Section 2 briefly 
introduces the field of biotechnology product development pipelines, key value drivers in the 
biotech industry and different practices of valuation models. In section 3, key determinants of 
human resource factors are presented along with the better model for scoring human capital in 
biotech valuation was introduced. Section 4 discusses the research methods used in this study. 
Section 5 deals with the results of the questionnaire based study; presentation of findings, and 
also discusses the rational of using various parameters to compute the value of human resource 
factor. Some limitations and criticism to the developed models are also discussed in this section. 
Section 6 concludes the study with recommendation for further research. 
 12 
 
2 THEORY 
Valuation in life science is the hybridization of science and art. Here, biotechnology valuation 
deviates from that of mainstream economics and finance due to some inherent characteristics of 
biotechnology firms.  The inherent characteristics of biotech companies can be better explored 
through the common language of product development cycles. Common language of product 
development cycle will enable various stakeholders to better understand this industry. Well 
defined path of product development will help financial community, collaborators, and licensors 
to value the product; helps the regulators to understand the pros and cons of the product; and 
helps the product developing start up Biotech Company to achieve their goals or to terminate the 
project. Based on the traits of R&D subjects, technological advancement, and characteristics of 
finished products, the financial community evaluates the product opportunity and makes 
investment decision (McElroy, 2004). The following Figure 1 represents the well-defined 
product development pipelines of biotech product. 
 
Figure 1: R&D pipeline for agriculture and pharma biotech product (McElroy, 2004). 
2.1 Unique industry factors 
Biotech firms are characterized by certain unique features that add complexity in valuation 
methodologies. Some complexities in valuating biotech companies include; high capital burn 
rate, lower survival index, uncertainty in input parameters, no availability of universally accepted 
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standard valuation methodology, interpretation etc. For biotech firms already having their 
product in the market, the valuation techniques can be applied with comparative ease. For newly 
developing firms, some complexities that need to be considered during the valuation process are 
as follows:  
Lengthy period: Long time period from inception of seminal idea to regulatory approval and 
commercialization of product is unique to biotech industry. 
State of pipeline: Number of products in the developing phase and their stage of development in 
product development pipeline determine the mortgage value of a company. Furthermore, Bratic, 
Tilton, & Balakrishnan (1997) have noted that any company, whose success and failure depends 
on only one product has a higher risk than company with diversified products in product 
development pipeline. 
Burn rate: High cost in developing and testing new technology results into R&D costs and thus 
the high capital burn rate. Despite the higher burn rate, success rate of biotech companies is low 
(Ratliff, 2003). This indicates a higher risk for the investors. 
Survival index: Smaller biotech companies have smaller survival index with minimum cash for 
R&D whereas larger companies have greater survival index and have more cash in hand to carry 
out lengthy and costly R&D phase.  
Strategic collaboration: Clustering and strategic alliances are dominant phenomenon in a biotech 
industry which has positive effect to the biotech companies. Very few companies have cash in 
hand to complete their lengthy R&D phase and enter the commercialization phase. So, in order 
to sustain in R&D phase requiring the significant amount of capital resources, establish strategic 
alliance with larger companies can be an option. This feature of biotech firm makes the valuation 
process more complex (Bratic, Tilton, & Balakrishnan, 1997). Strategic alliance formation 
influences internal flexibility during R&D phase as well as in external flexibility during a 
commercialization phase (Jagle, 1999). This flexibility adds more complexity to the valuation 
process. 
Changing technical, commercial and regulatory environment: National and international 
regulatory climate, competition on R&D, and market access often have some implications on the 
product pipelines of biotech companies.  The changing environment increases the risk and that in 
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turn brings deviation in discount rates and success probabilities. Finally, it influences the 
valuation process, and the value of the company (Arojarvi, 2001).  
Patents/ Intellectual property: Patent as the most important intangible asset has several 
implications in industrial dynamics. For example, it has positive impact on R&D activities and 
encourages innovation. Exclusive exercise of patent right provides market monopoly for limited 
duration which is the competitive advantage for firms holding patents. It affects the product life 
cycle and thus future cash flow. Thus, valuation depends largely on the market potential of 
patents (Arojarvi, 2001).  
2.2 Literature on valuation  
Valuation of a company is an indispensible part of company’s life because valuation not only 
provides basic information for companies’ deal with other partners for mergers and acquisitions 
but also forms the basis for economic value creation of the product or the company. Some of the 
common valuation methodologies that have been used in the field of finance and economics are 
based on balance sheet (book value, adjusted book value, liquidation value and substantial 
value), income statement (Value of earning, Value of multiples, Sales Multiples etc), mixed/ 
goodwill (Classic valuation method, Abbreviated goodwill income/Simplified Union of 
European Accounting Experts (UEC) method, UEC method, Indirect method, Anglo-Saxon 
Method/Direct Method, Annual Profit Purchase Method, Risk Bearing and Risk Free rate 
Method ), cash flow discounting (based on free cash flow, equity cash flow and debt cash flow ), 
value creation and options based methods such as real option methods (Fernandez, 2004). 
Decision tree method, binomial lattice and simulation methods are also used to provide more 
flexibility to DCF and Real Options valuation techniques (Bogdan & Villiger, 2010). 
2.2.1 Income based approach in business valuation 
Income approach is the most fundamental approach to valuation and is based on the economic 
principle of expectation. Primarily, it estimates the future returns of a business and then matches 
them with the risk associated along with the time. The value of a business lies in its intrinsic 
capacity of generating positive cash flow. This fundamental aspect of value is captured wisely by 
income based valuation approach (Flignor & Orozco, 2006). The value of a company is greatly 
driven by its potential higher financial return on invested capital and its potential to growth. 
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Thus, Koller, Goedhart, & Wessels (2010) have explained that the future cash flow projection 
depends upon possibility of its financial return and growth options potentials. Higher return and 
growth result in improved positive cash flow which in turn drives the business value. Thus, the 
cash flow measures the value of the company.  
There are three major components of income based method for business valuation, cash flow 
projection, IP asset’s economic life, and the discount rate equivalent to the investment risk along 
the time value of the capital invested. Income method is highly analytical as it is based on the 
future cash flow generating potential of present days IP assets (Flignor & Orozco, 2006). 
Discounted Cash Flow (DCF) is a method for the valuation of an attractiveness of investment 
opportunity of the company. Valuation based on DCF is carried out by estimating all free cash 
flows for a given period and then discounting the associated risks to find the present value for the 
future sum. It depends on detailed, careful forecast of financial items related to the business 
operations for specific period of time. The discount rate determination remains one of the 
important tasks in DCF and depends upon the associated risks and historic volatilities 
(Fernandez, 2004). There are various models based on discounted cash flow. All these models 
result into a same value of a company when applied properly. Koller, Goedhart, & Wessels 
(2010) have classified these DCF based models into the following types; 
 Entreprise Discounted Cash Flow, 
 Economic Profit, 
 Adjusted Present Value, 
 Capital Cash Flow, and, 
 Equity Cash Flow. 
2.2.1.1 Enterprise discounted cash flow 
Company’s operating cash flow forms the basis for Enterprise discounted cash flow. In other 
terms, it is the sum total of equity value and debt value of a company. Valuing business or 
operations by enterprise cash flow involves three major steps which can be presented as follows: 
 Analysis of company’s historical performance: Return On Invested Capital (ROIC), Free 
Cash Flow (FCF), Net Operating Profit Less Adjusted Tax (NOPLAT), growth, 
competitive position, Intellectual Property (IP) assets 
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 Projecting free cash flows after defining company’s operations and life of assets 
 Discounting projected the cash flow with Weighted Average Cost of Capital (WACC)1 
During the analysis of historical performance, it is possible to include illiquid investment from 
inside, but it is limited to rough guess for outside valuators. This limitation to outsiders is due to 
the fact that companies do not disclose discounted operations, excess real state, non consolidated 
subsidiaries and other non equity investments. Separation of operating and nonoperating assets is 
also advisable in order to make the risk of investment equivalent to the discount rate. When debt 
does not appear in the balance sheet, then the value of equity is overestimated which may turn 
into the company collapsing events (Koller, Goedhart, & Wessels, 2010). 
2.2.1.2 Economic profit based valuation model 
It is a performance based valuation technique where economic profit is obtained as the difference 
between revenues (ROIC) and cost, including cost of capital (WACC). WACC is the average of 
after tax cost of all components of capital structure of a company. 
Economic Profit = Invested Capital * (ROIC - WACC) 
US based multinational companies like Coca Cola, AT&T corporation evaluate and measure the 
management performance based on generated economic profit. Since this model relies on 
forecast as well as performance measurements, it can be the reliable valuation model for small as 
well as large scale businesses (Larrabee & Voss, 2013). Intrinsic value of a company lies in its 
potential to generate future cash flows. This potential is reflected through present performance. 
In addition to performance measurement, the economic profit model provides an insight about 
the way how the business can create value over a period of time, and investors future 
expectations are based on these values. Thus, it is also a management tool to assure the investors 
in their business  (Koller, Goedhart, & Wessels, 2010). 
ROIC and WACC are the key value drivers for economic profit. In saturated market, the ROIC 
will drop growth, becomes illusive and economic profit may be zero. This may drop the value of 
a company. For example, in early start up biotech companies, the net present value is negative 
                                                 
1
 WACC represents the weighted average of after tax costs of all financial resources of a company. These financial 
resources include; retained earnings, debt, common stocks, preferred stocks, and other different forms of equity. 
Weight on each source of finance is adjusted according to the risk associated with them. 
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and the intangible assets may not be able to generate the measurable cash flow despite their 
attractive market potential. In such situation, call option can be the better strategy to unlock 
future opportunities and attract further investment (Myers, 1977). Thus, Arojarvi (2001) has 
argued that this model of valuation is not feasible in case of biotechnology industry and 
emphasis on the valuation based on management flexibility and growth opportunities. 
2.2.1.3 Risk adjusted Net Present Value (rNPV) 
Future cash flows prediction with discount rate based on assumed constant WACC in Enterprise 
DCF and Economic profit model of valuation leads to another assumption that capital structure 
of a company is managed to a target debt to value ratio. However, more and more assumption in 
forecasting cash flows and little management flexibility may lead to distortion of real value. 
Though the capital structure of a company can be planned accordingly to manage the debt to 
value ratio, the process is complex and cumbersome (Koller, Goedhart, & Wessels, 2010). Thus, 
risk adjusted net present value can be the better option for company valuation. 
rNPV adopts the same principle as DCF and the discount rate is adjusted based on the probability 
of occurring of specific event in product life cycle. NPV assumes that all the risks in cash flow 
forecast through discount rates but rNPV takes into account the probability of the cash flow to 
occur before discounting. In biotech and pharma industry, the project development phases are 
highly regulated and standardized. Furthermore, product development phases in the project are 
distinct with different probability for each phase to succeed. The probabilities are often called 
attrition rate or the success rate. Based on these success rates (though based on historical data) 
probability of success of each phase is multiplied to the cash flow and then appropriate discount 
rates are applied.  
Steven Burrill, CEO of Burrill and Company, has given the real life cautionary explanation on 
valuation: “Notwithstanding the entire fancy math, the real way these tech companies are valued 
based on comparables…. the real life value is determined on the arm’s-length negotiation.” 
(Stewart, Allison, & Johnson, 2001). Despite this reality, Stewart, Allison, & Johnson (2001) 
belive on number game and argue that correct estimation lies on adequatly addressing the cost, 
risk and time inherent to product development. They emphasize on the fact that number game of 
valuation based on rNPV provides the rational basis for negotiation when the biotech 
entrepreneurs are approaching the venture community.  
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2.2.1.4 Capital cash flow 
In free cash flows method of valuation, the interest tax shield are excluded from the cost of 
capital and thus, decreases the cost of capital when after tax WACC is used. Business involving 
highly leveraged transaction, capital restructuring, project financing from various sources results 
in capital structure. With the change in capital structure, the weighed average cost of capital has 
to be estimated. This leads to technical problems in implementation of free cash flow valuation 
method.  
To overcome these risky cash flows, Ruback (2002) has proposed the capital cash flow method 
of valuation where, cash flow includes all the available cash including interest tax shield. He 
emphasized that, when the company manages debt-to-value ratio, free cash flow and interest tax 
shield are discounted at the same rate. Thus, the two flows, free cash flow and the interest tax 
shield can be represented by a single method known as capital cash flow (CCF).  
The FCF and CCF method lead to identical result with proportional debt to value ratio but, 
Koller, Goedhart, & Wessels (2010) claim that FCF valuation is superior to CCF. This is 
because, leverage independent NOPLAT and FCF can provide a measure for performance and 
competition. This leads to better cash flow projection and thus better valuation results. 
2.2.1.5 Cash flow to equity valuation model 
Unlike WACC based valuation models, cash flow to equity valuation directly values the equity 
by discounting the cash flows at the cost of equity. It can be calculated by the following formula, 
Equity Cash Flow = Net Income - Increase in Equity + Other Comprehensive Income 
Equity valuation model is used in financial institutions where financing and operating activities 
are inseparable from each other.  
2.2.2 Asset based approach in biotech valuation 
Asset based method, often called as cost approach, relies on the economic principle of 
substitution. This approach estimates the value of a business by estimating the cost of recreating 
the relevant business of similar economic utility (Certified Business Appraisals, LLC, 2012). The 
basis for valuation for asset approach is the financial statement, the balance sheet. Business 
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Resource Services (2007) mentions four assets based approaches for valuing a business; book 
value, adjusted book value, liquidation value and reproducible approach.  
Book value represents the net worth of a business obtained from the difference of total assets and 
total liabilities. It represents only the liquid assets and ignores the illiquid and thus book value 
remains far from the fair market value. The difference between assets and liabilities is the 
intangible assets and goodwill. In balance sheets they appear as cost incurred to obtain them. If it 
is not mentioned in the financial statements it needs to be adjusted in the book value to obtain the 
value close to fair market value. This adjustment results in the more correct and applicable 
valuation approach, the adjusted book value. 
Liquidation approach in business valuation does not consider the value of ongoing companies. 
Thus, this approach is not commonly used in biotech valuation. Reproducible approach focuses 
on the cost of reproducing the fixed assets of the business. Thus, in real business world value 
obtained from liquidation and reproducible approaches represent the lowest threshold of the 
business value that the prospective buyer can pay (Business Resource Services, 2007). 
Furthermore, in biotech companies, very little value is often left inside the company when staff 
has left the company. 
The above mentioned asset based valuation approaches that rely on balance sheet as its sole 
financial statement poorly incorporate the intangible assets and goodwill in the valuation 
process. Despite this fact, stock market values the biotech firm based on these financial 
statements (Hand, 2001). 
The productivity of biotech firms are the outcome of investment functions particularly the R&D 
expenditure in combination with bio-technical man power involved. Bio-scientists and bio-
engineers produce intellectual capital from R&D expenditure and translate the property to 
monetary form via sales, profit and equity market value. Thus, stock market value biotech firm 
based on financial statements with more emphasis on R&D expenditure (Hand, 2001). Higher 
the R&D expenditure in early stage biotech companies, higher will be their market value. Hand 
(2001) concluded that higher elasticity is observed in biotech firm’s equity market values when 
there is higher R&D spending in early stage R&D pipeline. The value elasticity decreases with 
spending in matured firms. 
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2.2.3 Market based approach in valuation 
Market based approach, also referred to as transactional method, relies on the comparison of the 
subject business to similar business that have actually been sold. Economic principle of 
competition is the foundation for this approach as it looks for the recently established market 
values of comparable business in order to value the subject business (Certified Business 
Appraisals, LLC, 2012). Flignor & Orozco (2006) consider this approach of valuation as the 
most appealing and reliable method as it provides direct value  for the intangible assets. Ensuring 
comparability remains the key factor to successful performance of transactional method. This 
method has limited applicability for valuing the small businesses because of scarce accessibility 
and reliability of comparable transaction from similar guideline businesses. Thus, screening and 
adjustment of comparable factors is like finding needle in a haystack (Dukes, 2006).  
Institute of Management Accountants (IMA) (2009) has classified this approach of business 
valuation in three subcategories viz, Sales of stock in same company, Sales of similar companies, 
and Guideline companies.  
2.2.3.1 Sales of stock in same company 
Sometimes a company may sale its stock at certain price which can be a basis for valuation of the 
same company. Though this simple approach sounds good, many flaws may occur while valuing 
a company on the basis of sold stocks. It is because; it may not reflect the fair market value due 
to certain restrictive agreements, time and economic environment, minority interest and 
controlling interests etc.  
2.2.3.2 Sales of similar private company 
Data of similar private company may be available but one cannot ensure with confidence that all 
the transactions are disclosed. If sufficient information on companies intrinsic value drivers such 
intangible assets, scope are available, then adjustment in baseline transaction can be made to 
enhance the rationality of valuation approach. Adjustment may range from complex statistical 
modeling that uses the multiples to experience based subjective adjustment (Flignor & Orozco, 
2006).  
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2.2.3.3 Guideline companies 
Publicly traded companies within same industry or similar related industry have similar risk 
factors and similar value drivers, and thus can provide better valuation measures through the use 
of multiples (Institute of Management Accountants (IMA), 2009).  
2.2.3.4 Use of multiples in market approach of valuation 
A well executed multiple analyses can be helpful in comparing the companies’ performance with 
its competitors, testing the plausibility of cash flows forecast and companies potential to create 
value than other counterparts (Koller, Goedhart, & Wessels, 2004). Many analysts use price to 
earnings (P/E) ratio to calculate their multiple and establish the fair market value of the 
company. However, Koller, Goedhart, & Wessels (2004) insist that deriving multiples based on 
P/E ratio can have many flaws even though identical companies are compared. This is because 
the P/E ratio mixes both operating and non-operating items. Thus, a carefully designed multiple 
analysis can only give us valuable insight on company value.  
Growth along with the return in invested capital drives the multiples and these multiple drivers 
can be better represented as enterprise value-to-EBITA multiple (forward looking estimates). 
The algebraic expression can be presented as below; 
 
 
Where;   
V= value, 
T= Taxes, 
EBITA= Earnings Before deduction of Interest, Tax and Amortization, 
g= Growth Rate 
ROIC= Return on Invested Capital 
WACC= Weight Adjusted Cost of Capital 
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Koller, Goedhart, & Wessels (2004) have suggested the guidelines for best practice in deriving 
multiples. These guidelines are illustrated in Figure 2. 
2.2.4 Real options approaches 
Traditional valuation methods are based on the assumption that projects meet their cash flow 
prediction, and managerial intervention has no or very limited role to play with any future risks. 
Managerial discretion and flexibility are not taken into account during the long life of a project     
(Trigeorgis, 1996).  
“The basic inadequacy of the NPV approach and other DCF approaches to capital budgeting is 
that they ignore, or cannot properly capture, management’s flexibility to adapt and revise later 
decisions (i.e., review its implicit operating strategy). The traditional NPV approach, in 
particular, makes implicit assumptions concerning an “expected scenario” of cash flows and 
presumes management’s commitment to a certain “operating strategy”.” (Trigeorgis, 1996). 
Comparable selection from similar ROIC and growth perspectives 
Use of multiples based on EBITA (enterprise value multiples) 
Use multiples based on forward looking multiples 
Adjust the enterprise-value multiple for non-operating item 
 
 
Figure 2: Steps for best applying multiples in market based valuation approach 
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Uncertainty underlying the future market development, regulatory frameworks, growth 
opportunities and value creation potential of IP assets in technology intensive companies are not 
addressed properly by traditional approaches of valuation. Discount rates and/or risk adjustments 
struggle insufficiently to manage the future uncertainty. Despite this fact, companies in biotech 
industries are often valued significantly high before they generate any sales even the company 
have highly negative NPV (Kellog & Charnes, 2000). 
Real options valuation techniques are based on the assumption that not all the decisions of a 
company or a project occur at early stage of their life. It is essential to make some decisions in 
the later stage of company’s life depending upon the techno-commercial environment. Thus, it 
takes into account the managerial flexibility. Managerial flexibility depends on the prudent act of 
the managers to maximize profit or minimize the loss and finally to increase the value of a 
company. Thus, Bogdan & Villiger (2010) have mentioned that real options consider flexibility 
as opposed to other traditional approaches, which have vaguely anticipated market conditions. It 
captures the market uncertainty and provides an opportunity for risk management to the 
managers through strategic thinking. The novelty of real options valuation lies in the 
conditioning of future decision as per the market condition rather than vague anticipation. 
The managerial flexibility in real option valuation is offered by the following options viz., option 
to differ, option to switch, option to expand or contract, option to abandon or license, option to 
growth and option to stage investment. 
According to Bogdan & Villiger (2010), these real options can be valued by four major methods; 
Formula based, Tree/Lattices, Simulations and Finite differences. 
2.2.4.1 Decision tree analysis 
Unaddressed uncertainty mounting on the cash flows based valuation approaches leads to the 
criticism on these traditional methods. Early stage biotech projects are full of expectation. 
According to Jagle (1999), technology intensive companies in USA have expectations’ share up 
to 70% of total value of a company. Thus, making effective plan with high commitment of 
utilizing present resources to future action is essential for managerial decision that can meet the 
expectation. Today’s decisions are directed by our future expectation and uncertainty paves the 
way of future decisions. Therefore, decisions should neither be made in isolation nor in terms of 
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sequence. Thus, for an effective long term plan, decisions are posed in terms of tree like fashion 
(Magee, 1964). 
Decision Tree Analysis (DTA) tries to address the uncertainty of discounted cash flow and NPV 
based traditional analytical methods by allowing managerial flexibility in future events (Magee, 
1964). This managerial flexibility is portrayed in a tree like fashion that resembles different paths 
for the life of the project. As a part of managerial flexibility, decisions are made at discrete 
points (nodes), and uncertainties are also resolved at these nodes. 
DTA shows its efficiency over traditional approaches in its ability to incorporate managerial 
flexibility. However, more options at the nodes make the decision tree more complex. Trigeorgis 
(1996) called this complexity as bush tree analysis. Furthermore, use of constant discount rate 
throughout the DTA process even when uncertainty is reduced at nodes, is the major flaw of this 
valuation model.  
2.2.5 Contingent claim analysis 
The Contingent Claim Analysis (CCA) method was developed as an improvement over DTA 
where the constant interest rate is replaced by risk-adjusted interest rate. In CCA, real 
probabilities and risk-adjusted interest rate of DTA are transformed to risk adjusted probabilities 
and risk free interest rate which is independent of projects risk structure (Schulmerich, 2010).  
Flexibility, collection of options associated with investment opportunity, is also well captured by 
CCA than DTA (Trigeorgis, 1996). 
2.3 Human resources and valuation in life science 
A golden triangle composed of finance, management and intellectual property is considered as an 
essential component for a complete biotech life cycle. Each of these three components should 
complement each other for the sustainability of biotech companies. Every evolutionary stage of 
biotech life cycle needs different human resource, perhaps the renewal of board structure and 
also the functional human capital (Collingham, 2004).  
The way by which intellectual capital lead to economic and market goals at enterprise level can 
be presented as follows in Figure 3. 
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Figure 3: Relationship between intellectual capacity and market goals Source: (Fitz-enz, 2009) 
As an essential component of the intellectual capital, human resource needs to be managed well. 
Being an elusive asset, measurement is not an easy task. To materialize the saying, “What gets 
measured gets managed,” the human value in a company needs to be measured (Weatherly, 
2003). With the advent of an era of innovation, the asset composition for a company has been 
changed. This change was reflected in terms of diminishing correlation between company’s 
accounting/financial data and market performance. The increasing difference between society 
audit transactions and stock market performance also reflects the value of capital accumulated 
(Vărzaru & Stancu, 2007). Almost 80% of company’s asset is human resources, intellectual 
properties and brand value; collectively known as intellectual capital. The intellectual capital is 
the key elements to create a holistic image of firm’s hidden value.  This dramatic shift of asset 
structure from its physical nature towards knowledge based abstract nature has created an issue 
of measurement of economic value of intangibles/intellectual capital including the human capital 
(OECD, 2006). 
With the advent of human capital measurement issues, it was practiced to be included as assets in 
balance sheet. Reflecting the human capital in the balance sheets served for two different 
purposes, namely; supporting investors’ decision and for internal decision-making process. This 
initial practice stimulated the emergence of two pioneer concepts of “Human Capital Theory” 
and “Human Relationship School”. Two methods of human capital quantification; historical cost 
method and cost replacement method were also proposed. Since then cost of hidden 
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performance, cost of opportunity methodology, and behavioral cost in work have been proposed 
(Vărzaru & Stancu, 2007). In addition, human resource accounting, cost accounting paradigm, 
surplus distribution paradigm and performance potential paradigm are also some efforts in 
capitalizing human capital in valuation. However, models are silent about the freedom of 
managers as individuals and also ignore the uncontrollable nature of human asset. In other 
words, they ignore the social and personal aspects of human resources. The company can retain 
the human capital, but it does not own it (Vărzaru & Stancu, 2007). Therefore, human 
values/human capital can hardly be expressed in monetary terms as accounting parameters. 
However, they are the value adders which attempt to convert the subjectively projected 
hypothetical corporate value to real life value (Scholz, 2007). 
 Assigning a value to human capital has been a contentious issue in human resource economics. 
The Organization for Economic Co-operation and Development (OECD) council meeting at 
ministerial level has also mentioned that intellectual capital is essential for sustaining economic 
growth of a company but the value creation is an outcome of sum total of human resource 
reflected via managerial activities (OECD, 2006). Almost all present days CEOs emphasize 
human as the most critical assets for them in the era of the knowledge economy. Thus, Kaye 
(2012) argues that paradigmatic shift from goods oriented business models to knowledge based 
innovative and service oriented era of 21
st
 century has challenged CEOs to materialize their 
rhetoric in language of accounting and finance. In an effort to convert rhetoric to practicality, 
various progresses in valuing human resources have been performed. Summary of these efforts is 
presented in Figure 4. 
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Figure 4: Progress pattern in human resource valuation Source: (Phillips, 2007) 
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3 HYPOTHESIS DEVELOPMENT 
The biotech company valuation models developed so far have perhaps failed to incorporate 
perhaps the most important factor, human resource factor, which leads to a discrepancy in real 
market value and the results obtained by the use of existing formulae. Though various works in 
human resource economics have leveraged an effort to develop the human value measurement 
tools, their applicability is limited due to the subjectivity of the models that are based on 
complex measuring factors. 
Value of a company is the outcome of total of tangible (physical assets) and intangible assets 
(intellectual capital). 
Value (Vbc) = Tangible assets (T) + Intangible assets (I) 
i.e., V (bc) = T (t) + I (t)         ……. (1) 
Where, bc = biotech company and t = total. 
Intangible asset is an outcome of a complex interplay between relational capital or overall 
market, human capital (human resources, process and culture) and intellectual property 
(technology and traditional intellectual capitals such as patent, trademark, copy rights, license 
etc.). Traditionally, intangible assets were presented as sum of relational, intellectual and human 
capital as shown in equation 2.  
Intangible assets (I) = (relational capital + human capital (including process and culture) + 
intellectual property (IP))        ….….. (2) 
This equation ignores the uncontrollable nature of human beings. A company can retain its 
human capital but does not own it. Therefore, the value of intangible assets of a company can be 
derived from accurate assessment of technology (product or service offered, license, copyright, 
patent etc), relational capital (customer preferences, suppliers, regulatory issues, brand value, 
competitors, emerging market trends etc) and the financial issues related to technology and 
relational capital.   
 
 
 29 
 
Technology seldom sells by itself.  It is not a solution but act as an enabler of human capacity 
and intelligence. On the other hand, translation of innovative technology to revenue requires 
efficient human resources. Thus, human are catalysts for technology and their offerings (Phillips, 
2007). According to (Edvinsson & Malone, 1999), corporate value does not arise directly from 
any of its intellectual capital components (human capital, relational capital and intellectual 
property) but it is a complex interplay between these factors. No matter how strong are the two 
other factors, weakness of the third factor misdirects the mission and ruins the company value. 
Among these factors, the company owns the IP assets and relational/ environmental capital but 
human capital cannot be an asset. Human capital can be retained by the company but it cannot be 
owned. Human resources, especially those on upper echelons create the market through 
innovation, develop strategies with changing business environment, and finally translate those 
strategies to operational success (Bossidy & Charan, 2002). This operational success determines 
the firm’s performance and finally the value of a company.   
Accurate 
technology 
assessment 
Accurate 
assessment 
of relational 
capital 
Accurate 
financial 
assessment 
of 
technology 
and relation 
Value of 
intangible 
assets of 
company 
Figure 5: Components of intangible assets 
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In this thesis, it is hypothesized that the intellectual capital translation efficiency of human 
resource of a company can be expressed in terms of human resource factor (hrf). The hrf can be a 
correction factor in an ideal value derived from the accurate assessment of relational, financial 
and technological capital. Thus, company valuation model can be diagrammatically expressed as 
in Figure 6. 
Figure 6: Diagrammatic representation showing relationship between various components of valuation 
with human resource factor 
Mathematically, value of a biotech company as mentioned in equation (1) can be expressed as 
V (bc) = T (t) + I (t)  
Or, V (bc) =T + I   …………………..(3) 
Where, V (bc) = value of biotech company 
  = hrf, 
 = market function for tangible assets value, 
Human resource 
in terms of human 
resource factor 
(hrf) 
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relational 
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Market 
value of 
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Market 
value of 
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T= value of tangible assets, and, 
 I = value of intangibles obtained from existing valuation models (for example, CCA model of 
valuation which consider intangible assets as an outcome of relational capital and intellectual 
property) 
The market value of a company is a complex interplay between the tangible and intangible assets 
as shown in the Figure 7. 
 
Intellectual property 
Market value of biotech firm 
Tangibles/ Financial capital Intangibles/ Intellectual capital 
Structural capital Human capital 
Work force capital Leadership capital Environmental capital 
Patents 
Trademarks 
Trade secret 
Knowledge 
databases 
Customer relation 
Supplier relation 
Relationship 
networks 
Goodwill  
Leadership academic 
qualification 
Leadership experience 
Breed of leadership  
 Stage specific 
management practice 
 Department specific 
management practice 
Scientific ties 
Team work/ Workforce 
interaction 
Succession planning 
Motivation/ retention 
strategy 
Knowledge continuity  
Figure 7: Diagrammatic representation of various components contributing to establishing the market 
value of human capital proportion of biotech firms 
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3.1 Human resource factor 
The existing human capital of a firm is responsible for converting the market potential of firms’ 
intangible assets to actual market value. Ideal human capital seldom exists in a business 
environment because of highly volatile and mobile nature of human capital. Thus, firm’s 
intangible asset is rarely translated to market value in its full potential. In this thesis, it is 
proposed that translational capacity of human capital is expressed in terms of human resource 
factor (hrf) which is defined by firm-specific human resource indicators. The firm-specific 
human resource indicators for biotech companies proposed in this study include the following; 
Leadership capital: 
 CEO effect 
 Breed of managers 
Workforce capital: 
 Ties with star scientists 
 Knowledge continuity 
 Succession planning 
 HR interaction 
3.1.1 Breed of managers 
Knowledge and academic qualification in the field of science and management are essential for 
the successful management of the biotech company. Citing an example of Eli Lily and 
Company’s success in scientific innovation, Powell (2013) argues that data drives the decision 
and direction; and scientists at the leadership position can drive innovation successfully. 
However, this may not be the universal case. In contrast to this argument, Smart (1998) 
emphasizes on the project development stage-specific human resources. He argues that the early 
stage biotechnology companies can be better managed by scientific leaders whereas the 
commercial stage company is better managed by experienced business managers. He further 
adds that many investors in the biotech industry fail by backing the technical people with great 
technological knowledge even in later stage of commercialization. Specific entrepreneurial 
ownership in a leading position highly enhances the human resource value of a company. 
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The managing director of  Royal and Sun Alliance (RSA) Singapore, Laura Thomas, also 
analyze the attributes of Biotech CEOs and focuses on the three CEO phases of a biotech 
company similar to the stage-specific HR arguments of Smart (1998) (Thomas, 2009). She 
argues that there cannot be “one size fits all” CEOs in biotech firms. Fair degree of leadership 
specialization for specific development stages can only boost the firm value. According to 
Thomas, three different leadership qualities are essential for three different stages; 1) founder 
scientist with more scientific and technical staffs in early stage of a company (intensive R&D) 
stage, 2) second stage specially deals with later stage of clinical trials, market strategy 
development and IPO, therefore, CEOs with proven capabilities in marketing and fundraising 
through IPO are essential, 3) third stage specifically deals with production, commercial and stock 
market regulation where CEOs with prior experience in commercial pipelines and stock market 
regulation are essential for leading the biotech firm successfully.   
In similar arguments to Laura Thomas and Smart, Andreas Foller points out that company’s 
success is not solely determined by ideas and concept, but the management team plays a crucial 
role. He argues that European biotech firms remain un-stocked and have delayed consolidation 
as compared to that of United States. This bigger difference between these two is the 
management practice; development stage-specific management practice in US and the Europeans 
are lagging far behind in this matter (Föller, 2002). Figure 8 illustrates the change in human 
capital needs with growth phases of biotech companies. 
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Figure 8: Human capitals need changing with growth phase in the biotechnology company Source:  
(Collingham, 2004) 
3.1.2 Ties with star scientists 
Firms having ties with star scientist have higher chances of R&D breakthrough for valuable 
commercial product and thus have a direct influence in firm’s market value.  In an effort to 
determine the effect of intellectual human capital on firms’ market value, (Darby, Liu, & Zucker, 
2009), found that market value of a firm with an article written by its star scientist  increases by 
7.3% as compared to its counterparts. However, there exists a concave relation between the ties 
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and the probability of innovation. Darby, Liu, & Zucker (2009) have expressed this concave 
relation via mathematical expression as; 
 X= ties 
½
.
  
Where, “X” represents the probability of innovation and “ties” represents the number of 
scientific staffs (intellectual human capital) of a biotech company. 
This equation reflects the decreasing effect of firms’ intellectual human capital on technological 
innovation with increase in star scientist ties. Darby, Liu, & Zucker (2009), explain this 
phenomenon as diminishing marginal product. The innovation has a direct positive relation with 
the value of a company.  
Joint collaboration between firm scientists and star university scientists improves the firm 
technological performance provided that they have joint research collaboration for innovative 
technological breakthrough (Colen, Belderbos, Leten, & Kelchtermans, 2014); (Zucker & Darby, 
1995). However, Colen, Belderbos, Leten, & Kelchtermans (2014), have also suggested that it is 
a real managerial challenge to convert the innovative challenge to its full potential. This 
collaboration also has the competitive implications. Zucker & Darby (1995), have found that 
collaborative research publication between firm scientists and academic stars is a key 
determinant about where and when the firm started with that technological innovation. Through 
their descriptive research about the virtuous cycle of productivity in bioscience, they have found 
that for every 9 joint article publications, there will be 3 product in development pipeline, 1 in 
market and more than 1500  employees employed.  
Collaboration of firm scientists with star scientists enhance the knowledge transfer which in turn 
stimulate technological innovation. Greater the stimulation towards technological innovation 
greater will be a patent application applied by the firm. In addition to this, core scientists/star 
scientists working in the biotech firm laboratory also increase the firms absorptive capacity  
(Furukawaa & Gotob, 2006; Sedita & Shichijo, 2008). In photocatalyst sector, higher R&D 
productivity, higher absorption and greater experience has been observed when firm scientist 
have collaborative research with star consulting scientist and consulting scientist. Furthermore, 
impact on R&D productivity (expressed in terms of number of patents/ patent applications) is 
double when the collaboration is with star consulting scientist in comparison to consulting 
 36 
 
scientist (Sedita & Shichijo, 2008). From IPO perspective, the probability that non-public firms 
go public increases with their science base, i.e., the quality of a science base of the firm 
determines its probability of going public. This probability in turn depends on the tie with star 
academic scientists  (Darby & Zucker, 2002). 
3.1.3 Knowledge continuity 
Knowledge depreciation prevention 
Exponential growth of the commercial field of biotechnology has made the technological capital 
under immense competitive pressure. This competitive environment has made the R&D 
investment riskier. Like all knowledge capital, technological knowledge capital can be gained or 
accumulated as well as depreciated. Knowledge capital in the technology sector is gained from 
two major activities; “learning by doing” and “learning by searching”. Here, Grubler & Nemet 
(2012) refer “learning by doing” activities like production and market deployment and “learning 
by searching” activities as firms R&D activities. They also argue that knowledge gained from 
experience is more susceptible to depreciation than scientific knowledge obtained from 
systematically organized experiment, peer review and dissemination.  
Further, knowledge capital is not traded in secondhand market, thus Hall, (2007), argues that 
depreciation has a serious effect in rate of return on R&D expenses and finally to the market 
value of the firm.  Knowledge depreciation rate varies from as high as 95% in the service 
industry to an average depreciation of 20-40% and knowledge depreciation of biotech and 
pharma varies from 15-20% (Hall, 2007). In a similar study, Grubler & Nemet, (2012) pointed 
out that high staff turnover and rapid technological obsolescence are the major events that 
leverage the knowledge depreciation rate. Thus, they suggest for stable gradually rising 
trajectory of R&D is essential rather than the boom and bust cycles for constant recharge of 
knowledge in order to combat depreciation. Policy support is also essential to mitigate the high 
staff turnover rate. In addition, training, workshop, conference and internship, public disclosure 
through scientific papers and patent application are also essential for preventing the 
technological knowledge depreciation.  
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Motivation and incentives 
According to agency theory, firms’ employees act in the interest of its shareholders. To 
maximize the interest of shareholders, firm can adapt various mechanisms. Among these 
mechanisms, incentive schemes that reward the executives financially are the most prominent 
ones. Furthermore, shareholders do not have complete information about the firm and the 
executive courses of actions are not completely observable to the shareholders. In such situation, 
providing best incentive package to the executives in order to take desired course of action that 
favors shareholders interest is the only solution. These incentive schemes are based on the belief 
that firms profit are the function of managerial efforts (Coles, McWilliams, & Sen, 2001). 
Among these incentive options right to purchase the share of the firm is gaining importance. As 
the executive ownership increases in a firm, the executive actions are directed towards 
maximizing the firms’ value. This results in a closer alignment between the outside shareholders 
and the firm executives (Smith, 2008). 
While examining the manufacturing firms’ executive compensation structure, Mehran, (1995) 
found that incentive compensation is a good motivator for the firm leadership to increase firm 
value. His research also found that the form of compensation rather than the level of 
compensation have higher degree of motivation. Highly R&D intensive, highly volatile and 
highly competitive firms exercise stock option as one of the most effective strategies for highly 
valuable employee retention. Lin (2009), in his study about stock options and their design in 
Taiwanese firm has discovered that larger and profitable firms that have high market to book 
ratio grant stock options to valuable employees. Furthermore, the study showed negative relation 
between R&D intensity and volatility with the retirement. Designing low valued stock options 
for retiring employees deters retirement and thus enhances the retention. Pasternack & 
Rosenberg (2002), while studying “the impact of stock option incentives on investment and firm 
value”, have found that it has the significant impact on firm value. They emphasized that stock 
options incentives are used as executive remunerations to align the interest of managers with 
those of shareholders.  
Michael Francisco in his article “Rising compensation for Biotech R&D officers” present the 
annual direct compensation packages from Bio world executive compensation report 2013 
(Francisco, 2013). The annual compensation packages for biopharmaceutical executives were as 
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follows; long term incentives (41.1%), attractive salary (43.85%), payment bonus (12.76%) and 
other types of incentives nearly 1% (Francisco, 2013). These figures also emphasise the 
importance of long-term incentives such as stock options and equity-based option to align the 
executive interests with that of shareholders in order to maximize the firm market value. 
During the comparative study on Private Equity (PE) firms and public companies, Leslie & 
Oyer, (2008) have documented that PE firms use stronger incentives for their top executives, and 
have higher operational profitability and higher efficiency. Quantitative assessment from 
comparison showed that EBITDA/Total asset of PE-owned firm was one-seventh higher than the 
comparable public firm. This is because PE firms increase the value of a company by increasing 
the management through incentives, improved governance and greater disciplines (Leslie & 
Oyer, 2008).  
3.1.4 Succession planning 
Sustained excellence in CEO succession with seamless transition usually results in better 
performance of biotech firms. Succession planning is an important tool of the overall process of 
corporate governance, but many corporate giants lack in action on succession planning within 
their firm despite their interest. A survey conducted by Korn/Ferry Institute over corporate 
leaders revealed that nearly 98% of the corporate leaders consider succession planning as an 
important tool in corporate governance but only 35% have such plans (Korn Ferry Institute, 
2010). Succession planning is not in the priority of many companies because of poor dynamics 
between CEOs and board of directors, lack of well-defined responsibilities or unavailability of 
CEO ready talent within the company. But, more importantly the personality, power, ego and 
mortality that lies at the heart of succession planning (Cascio, 2011).  
Succession planning usually focuses on the internal candidate. Sometimes, when the board feels 
that a change is essential than continuity or when things are not going well, the board of directors 
seeks for the outside successor. Findings by Falato & Kadyrzhanova, (2012) showed that the 
outsider CEOs have better performance by 4% excess return. Addressing this issue, Khurana & 
Nohria, (2000) mentioned that the process of CEO turnover is a dual process of succession and 
precession which cannot be viewed independently. Furthermore, these events can be natural or 
forced process. The firm performances differ according to the nature of the event. Forces 
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turnover followed by outside succession increases the firm performance by 4.4% whereas, 
natural turnover followed by outsider succession results in declining the performance by up to 
5.8%. However, forced succession followed by insider and natural turnover followed by insider 
has insignificant change in firm performance (Khurana & Nohria, 2000).  
Improvement in firm performance after outsider succession is temporary. The outsiders think 
that they are not bound by social contract with employees. So, they make some bolder short term 
change and may avoid key peoples, are good at cost-cutting and divestment. These activities may 
lead to dry up the opportunities and is the way towards disruption of the firm (Steingraber, 
2011). However, recruiting the outsider may lead to loss of senior executive that means the loss 
of knowledge (Cascio, 2011). Greater cost in acquiring firm-specific knowledge, greater 
settlement time for the outsider, lower the incentives to perform for the insiders as the path to 
promotion is hindered (Naveen, 2006). Thus, the outsider successor may benefit the firm 
operation but a subsequent loss of senior executives may outweigh any gains that come from 
hiring the outside successor. Firm with greater complexity in operational activities should groom 
internal candidate for the succession in order to avoid the high cost of knowledge transfer and 
expertise to the outsider (Naveen, 2006). Furthermore, Volery, Doclo, Munton, & Sheaand 
(2007) have mentioned that high-risk ventures have more career risk, and it is difficult to find the 
appropriate human resources. Thus, home grown CEOs with a seamless transition has been 
proved to be fruitful in the biotech giant Amgen (Gordon & Philip, 2009). 
In an effort to find a solution about this pressing question of succession, Steingraber (2011) with 
Kelley, School of Business examined the leadership of 500 Standard and Poor’s Financial 
Services LLC (S&P) firms
2
. They measured the performance in 7 different metrics which cover 
productivity, growth and margin. They found that 36 non-financial S&P firms which cover 25 
different sectors were continuously leading the list with average productivity of 13%. They have 
also claimed that no outsider CEOs surpass this number for 20 years in these non-financial S&P 
500 companies. Thus, they attribute this success to the home-grown leadership (Steingraber, 
2011). This finding was also supported by the evidence from McDonalds and Apple CEOs 
                                                 
2
 S&P is a USA based financial company well known for its financial services. It regularly publishes the financial 
research and analysis of stocks and bonds of 502 US companies and lists these companies as per their value (more 
valuable companies are given more indices). 
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insider succession where the share price has increased steadily after their announcement that they 
are working on insider succession planning (Adams, 2012). 
3.1.5 Human resource interaction effect 
Human resources operate as in different departments as separate organic units. Thus, practice of 
team work, interdepartmental communication and knowledge exchange is essential for 
enhancing the value of human resources. Deep level diversity, surface level diversity, face to 
face meetings also has a significant impact on firm performance (York, McCarthy, & Arnold, 
2009). 
Furthermore, the inseparable tie between freedom to work and financial accountability of human 
resources in Biotechnology Company encourages the practice of organic life within the 
company. The small, redundant units have a freedom to operate to meet their targets while 
ensuring the survival of the company as a whole increases the probability of innovation. This 
finally leads to higher market value of a company (Li & Halal, 2002).  
Interaction of various parameters such as technology, firm’s age, diversity in employee and 
management, functional heterogeneity etc. resulted in 7% variation in market performance as a 
result of productivity and sales growth (Amason, Shrader, & Tompson, 2006). 
3.1.6 CEO effect 
Decision making and strategic actions determine the move that finally paves the way towards the 
achievement of the overall goal of the company (Matvieiets, 2012). The CEO is considered to be 
the final individual to make decisions and take strategic actions and thus drives the company 
towards specific goals. Thus, quality of CEOs affects the strategic actions, financial performance 
and finally the value of a company. Higher qualities CEOs have proper knowledge of industry 
value chain and profitability. Thus, they choose better projects, implement them effectively, 
maintain a balance between debt and equity, and finally lower the cost of capital of the company. 
These actions of quality managers convey the intrinsic value of the firm to the market that results 
in better IPO performance and also higher valuation of a company (Rakhmayil & Yuce, 2013). 
Mackey (2008) adopted a new methodological approach to determine the impact of CEOs on 
firm performance and found that CEOs have the substantial impact (about 30%) on firm 
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performance. Further, he found that CEO effect was found to be more influential than industry 
effect and corporate effect. 
Qualification 
According to Matvieiets (2012), CEOs education is among the list of drivers that leads the 
company and the shareholder towards the better wealth. While studying the effect of education 
and experience of senior executives on firm performance, Rakhmayil & Yuce (2008) found that 
not only the MBA degree of executives but also the university form which they are graduated 
affect the firm valuation while adjusting the firm age and industry effect as constant.  
MBA degree holders seem to follow short term goals, stability-oriented and have better financial 
performance while the technical executives are found to have higher stock return by about 4.69% 
but the performance is rather volatile. Furthermore, citing the findings from Kaplan (2007),  
Cimerova (2012) has mentioned that interpersonal skills (soft) skills are overvalued while hiring 
the senior executives but the executive skills (hard skills) which are the outcome of qualification 
and experience matter in company success (Cimerova, 2012)  
Experience 
In a cross section study of expansion stage companies, Hutzschenreuter & Horstkotte (2013) 
found that international experience and experience of teamwork positively moderate the cultural 
differences and firm performance which finally lead to improved firm performance. CEOs’ 
diverse experience reflects diversity of CEOs’ skills and capability to bear and manage risks. In 
words of Ryan & Wang (2012), this attribute is known as the general human capital. This general 
human capital improves the firms that are experiencing revenue shock and poor stock 
performance. Thus, diverse experience of CEOs is helpful in increasing firm value and firm 
performance of those firms that has performed poorly and need the strategic directional change. 
They attribute this positive change in firm performance by diverse experienced CEOs is by 
changing the firm policies (Ryan & Wang, 2012). Economics and MBA degree holder CEOs are 
more growth oriented and have less volatile firm performance. Leadership with higher technical 
education has more volatile firm performance.  
3.2 Introduction of the model 
Human capital creates economic value of a business firm through the application of set of skills, 
intelligence and know-how. As mentioned in section 3.1, breed of managers, star scientists, 
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knowledge continuity, succession planning, HR interaction, and CEO effect are the most 
important indicators of human capital in a biotech company. In this thesis, these indicators are 
used to define the human capital. The following model is introduced to define the human capital 
in terms of hrf (). 
= X1 V1 + X2 V2 + X3V3 +X4 V4 + X5V5 + X6 V6  
Where, X1..............X6 represent the constant for the variables V1…………V6 
V1= Breed of managers 
V2= Ties with star scientists 
V3= Knowledge continuity 
V4= Succession planning 
V5= Human resource interaction effect 
V6= CEO effect 
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4 METHODOLOGY 
4.1 Content analysis of valuation models 
Literature review for different practice in valuation models was performed to identify the various 
issues, trends, best practices and shortcoming of existing valuation models. Content analysis of 
income based, asset based, market based and real options approaches was performed. Content 
analysis revealed that the human resource factor was found to be lacking in these models which 
made these models incomplete. 
4.2 Identification of indicators for human value factor 
Biotechnology industry specific human resource indicators were identified which are presented 
in two specific headings 
 Leadership based indicators 
 CEO Effect (CEO Qualification and Experience) 
 Breed of Managers (Stage Specific Managers) 
 Work force based indicators 
 Scientific ties 
 Human resource interaction effect 
 Succession planning (human resource source and succession) 
 Knowledge continuity  (knowledge prevention strategy, knowledge continuity 
and motivation/ retention strategy) 
4.3 Assigning weight to each human resource indicators 
Each indicator is given a specific weight measured in terms of percentage. The weight assigned 
is partially based on already established numbers as specified by previous researches and 
partially as hypothesis based on literature available. Mackey, (2008) has mentioned that nearly 
30% variance in firm performance is atributed to CEOs and this effect is considered to be more 
important that industry effect. Similarly, interaction of various human resource related factors 
such as functional heterogeneity, management diversity, personal communication and 
interaction, technological changes etc explain 7% variance in firm performance as explained by 
profitability and market performance (Amason, Shrader, & Tompson, 2006). Darby & Zucker, 
(2002) have mentioned that star scientist can have 7% impact on variance in firm market value 
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through the publication of an article. Percentage variation in stock market performance of well 
established companies like Hewlett Packard (HP) and Bank of America was largely attributed to 
succession planning (Steingraber, 2011). This forms the basis of assigning weight to effect of 
succession planning on human capital.  
Preventing knowledge depreciation and retention of key employees are the two major aspects of 
knowledge continuity. Since knowledge is major capital for technology intensive industries like 
biotech industries, firm value depreciates along with the depreciation in knowledge. Application 
of strategies for preventing knowledge depreciation prevents the depreciation of firm value (Hall, 
2007). This forms for the basis of assigning weight for knowledge continuity. 
Breed of managers is biotech firm specific indicator newly introduced in this study.  Though, no 
numerical data are available, previous research by Föller, (2002), Smart, (1998) and Thomas, 
(2009) forms the basis of assumption that breed of managers have 15% effect on human capital 
of biotech firms. Table 1 summarizes the source of literature that supported the weight assigned 
to each human resource factor indicator. 
Table 1: Assigned weight for different human resource indicators 
S. 
No. 
Indicators 
Weight 
Assigned 
References 
1 CEO Effect 30% (Mackey, 2008) 
2 Star Scientists 7% (Darby & Zucker, 2002) 
3 Motivation And Retention 13% (Leslie & Oyer, 2008) 
4 Succession Planning 13% (Steingraber, 2011) 
5 
Knowledge depreciation and 
Prevention 
15% (Hall, 2007) 
6 Human resource interaction effect 7% 
(Amason, Shrader, & Tompson, 
2006) 
7 Breed of Managers 15%  (Smart (1998); Thomas, (2009) ) 
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4.4 Development of scorecard model measuring human resource factor 
A linear scorecard model for measuring the human capital in terms of human resource factor is 
introduced in this thesis as follows; 
= 15% V1 + 7% V2 + 28% V3 +13% V4 + 7%V5 + 30% V6 
At the same time can be argued that this model is relevant as a component for valuing the actual 
market value of a biotech company. 
4.5 Questionnaire 
Three different types of questions were included in a set of questionnaire. It consists of the 
following:  
 Yes/No questions, 
 Opinion questions (answers are expressed in Likert Scale3) and, 
 Open format questions (information that cannot be obtained through Yes/No 
questions and Likert scale is presented through open format questions.  
The questionnaire developed for the purpose of collecting data is given in APPENDIX I 
4.6 Data collection via questionnaire-based interview 
Information regarding the human resource of a company is often regarded as confidential. So, the 
response rate would have been insignificant if it had been performed via mail questionnaires to 
thousands of respondents. Furthermore, technical nature of some indicators introduced in this 
model is new to the respondents. So, appropriate and precise answer could only be an 
imagination. Therefore, a 40-50 minute long interview based on the set of questionnaire was 
performed with Senior Executives (especially CEOs) of five Norwegian Biotechnology 
Companies located in Hamar and Oslo. Selection of companies was done in order to cover the 
representative of different stages (early stage biotech companies and commercial stage biotech 
companies), different field (plant breeding industry, blue, green and red biotechnology 
companies) of biotechnology industry. 
 
                                                 
3
 Likert Scale is a rating scale used for scaling responses in various types of survey research. 
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4.7 Data analysis and interpretation 
Answers obtained from questionnaire-based interview were used to compute the efficiency of a 
company in each of the indicators that determine the overall human resource factor. For that 
purpose, certain assumptions were made.  
 Yes/No questions: For each yes/no question; 1 or 100% is assigned to “Yes” answer 
and for” No” answer 0 or 0% was assigned. 
 Opinion questions: Opinion questions were expressed in 1-5 likert scale. The score in 
likert scale was converted into corresponding quartiles. 1=0; 2=25%; 3=50%; 4=75% 
and 5=100%. 
 Open format questions: Answers obtained from open format questions were used to 
derive the conclusion to certain attribute or parameter. For example, education of 
CEOs was expressed in different levels. Higher level of education was given higher 
value and lower level is given lower value as other answers in Likert scale. In another 
example, CEOs graduating from top 100 universities (according to times higher 
education ranking) is given 100% score and no score for others. 
4.8 Presentation of findings  
The findings from the interviews were presented in tabular form. Furthermore, sensitivity 
analysis was performed to see the impact of indicators on human resource factor. 
4.9 Sources of errors 
Use of novel and technical terms might be misunderstood by the respondents and there could be 
the probability of obtaining incorrect information. To avoid the probability of such error indirect 
questions were used to derive the inference for such parameters (for example, breed of managers, 
succession planning). 
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5 RESULT AND DISCUSSION 
This section presents the findings from questionnaire based interviews. Human resource practice 
and status of human resource indicators, as proposed in the model are discussed. Human resource 
capacity of companies under study is calculated from the indicator values and presented in terms 
of human resource factor (hrf). 
5.1 Breed of managers 
Biotech industry straddles on two distinct and independent disciplines viz., science and 
commerce. This nature of biotech industry places unique demand on executive characteristics. 
The management of biotech industry needs to reconcile research primacy with urgency in market 
profitability. Imitation of managerial styles from other corporations does not work. Although 
many managers are sufficiently intuitive enough for leading biotech industries, formal/academic 
learning can simplify this daunting task. Thus, breed of managers with mastery in science and 
commerce will leverage the firm competitiveness. 
During this study, all the five companies were found to be practicing the stage-specific 
management. The management practice in terms of breed of managers has the following effect 
on hrf. Findings on effect of breed of managers on human capital are summarized in Table 2. 
Table 2: Effect of breed of managers on hrf 
S. No. Company Indicator value Percentage contribution to hrf 
1 A 100 15 
2 B 100 15 
3 C 100 15 
4 D 100 15 
5 E 100 15 
Among the five companies interviewed, four of them are in commercial stage and are managed 
by managers with commercial background where one company was in early stage of its clinical 
trial managed by scientist. All commercial stage companies have their products in the market and 
also have their products in product development pipelines. Company C has highest number of 
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products in market (>15) followed by B (10-15), C (6-10), E (<5). Company C has more than 
fifteen products in its product development pipeline while all other have 1 to 5 products in their 
pipelines. In addition, the commercial stage companies have well-organized departments to 
conduct their specific activities of R&D, marketing (national and international), finance etc. 
Company D is in early stage of operation and still has a long way to present itself with specific 
departments. Furthermore, two companies, A and E were established with the R&D outputs from 
their parent organization.  They entered directly into commercial phase with well experienced 
managers and continuing the own R&D activities.  
This, practice of management is in line with stage-specific management practice put forth by 
(Föller, 2002); (Thomas, 2009); (Smart, 1998) and (Parker, 2001). In early stage companies, 
founders, especially the scientists, are in the management team because of lower need of 
management sophistication, greater focus on successful R&D process and getting intellectual 
property of broad scope and value. However, with an increase in complexity of the organization 
firm need the managerial sophistication and thus managers lead the commercial stage well. 
Supporting this idea of stage-specific management, Föller, (2002) further stressed that European 
biotech sector falls behind US biotech sector as the founder CEOs are considered potential to 
lead the operational stage of a company also, which is far away from the reality. In contrast to his 
argument, this pilot scale study finds the practice of stage specific management in Norwegian 
biotech sector.  
For better market performance, these companies should practice a detailed stage-specific 
management practice in each stages of their product lifecycle, where, stage specific management 
resembles the breed of managers in a company. For this practice, managerial succession with 
stage of product in the pipeline is an essential activity. Figure 9 presents the diagrammatic 
illustration of managerial changes necessary with age of Biotechnology Company. 
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5.2 Ties with star scientists 
As mentioned earlier in section 3.1.2, quality of scientists and scientific ties, frequency of 
research publication, research collaboration, and presence of scientists in board or as venture 
capitalists have significant impact on firm performance and finally the firm value in research-
intensive industry such as biotechnology. These parameters were used to evaluate the star 
scientist indicator in order to determine its effect on hrf value. 
The study on star scientist effect of five biotech companies shows that Company B has the 
highest star scientist effect to human resource factor followed by Company E, and Company C 
has the lowest. This effect of each company and corresponding effect on hrf can be presented as 
below in Table 3. 
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Table 3: Star scientist effect on hrf 
S. No. Company Indicator value Percentage contribution to hrf 
1 A 62.0 4.3 
2 B 83.8 5.9 
3 C 50.0 3.5 
4 D 66.7 4.7 
5 E 70.8 5.0 
Among the five companies studied, only Company B has scientific staffs of more than ten which 
indicates that the firm has more intensive R&D activities than other comparable firms under 
study. Regarding the publication of scientific findings, CEO of Company C revealed that their 
scientists are not allowed to publish their findings in scientific journals. This practice was not 
found in other companies under study. Restriction to publish the finding by the scientific may 
retard the pace of innovation in this exponentially growing field of biotechnology. Company B 
has more than 20 scientific publications followed by Company E. Greater the number of articles 
published by firm scientists, greater will be the probability of innovation and hence the market 
value of the firm. Finding by Zucker & Darby, (1995) also support this relation, which states that 
articles are the indicators of firm knowledge capacity which determine success. Furthermore, 
their finding suggests that a single article publication by firm star scientist increases the firm’s 
market value by 7.3%.  
Quality of scientist also affects the firm innovative performance. Presence of star consulting 
scientist can contribute the scientific community through authorship and the industry via 
patenting thus leveraging R&D productivity. Similarly, consulting scientist can speak the firm 
language (Sedita & Shichijo, 2008). Among the company studied, company A has relatively 
lower base on scientific staff quality as compared to others, which are well equipped with star 
consulting scientists.  
Sometimes, R&D activities are entangled with complex strategic decision-making process. In 
such cases, human capital of directors plays a significant role. Presence of board members with 
scientific background can provide valuable input that leverages the strategic decision making 
process (Kalyta, 2013). Citing the findings by Kalyta (2013); Abdoli, Panahi, & Rahimiyan 
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(2013) have mentioned that significant impact of board’s human capital was observed in US 
public firms. The appointment of director scientists in the firm resulted in increase in 1% of 
stock price in 3 days period and abnormal return of 2.5% in a year after the event. This finding 
clearly signifies the importance of board’s scientific human capital in firms’ value. In this study, 
company C, D and E, either have scientists in their management board or venture capitalist-
scientists as investor.  Thus, their R&D activities can be enhanced through valuable inputs from 
scientists in board as well as by venture capitalist-scientists. Company B, which has better score 
on star scientist effect has farmers as investors and board members. It can further improve its 
human capital by inviting scientists in its board or scientists as investors. Similar activity by 
company A can also uplift its scientific human capital, which ultimately leads to better market 
performance. 
5.3 Knowledge continuity 
Knowledge capital is an indispensible component of organizations competitive advantage and 
hence the driver of firm value. Thus, it should be managed effectively and transferred continually 
to the successor in order to prevent decay and deprecation. In addition to that, continuous 
generation of knowledge is essential to mitigate the depreciation problem (Husman, 2001). 
Decay occurring through the loss of expertise can be minimized through effective knowledge 
management, employee motivation and retention techniques. Similarly, knowledge generation is 
equally important as knowledge depreciation prevention for continuity of knowledge. Learning 
by searching approach (example, R&D activities) of knowledge generation is common in biotech 
industry. In addition, learning by doing approach (training, workshop, internship, single loop 
learning, double loop learning, vertical integration of academia, public disclosure through patent, 
patent application/plant breeder’s rights, adapting talent development pool) is also important for 
generating knowledge. 
Executives from all five company interviewed considered knowledge continuity as the most 
important factor for biotech firm’s competitive advantage. They also emphasized the importance 
of knowledge continuity as a competitive advantage for firms in exponentially growing biotech 
sector. However, the implementation of this consideration was found to be limited. Company B 
has better practice for knowledge continuity with about 70% whereas Company D has the poorer 
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practice accounting 50% of its full potential. The summary of results for knowledge continuity 
can be presented as follows in Table 4. 
Table 4: Company wise effect of knowledge continuity on hrf 
S. No. Company Indicator value Percentage contribution to hrf 
1 A 56.25 15.75 
2 B 69.89 19.57 
3 C 57.81 16.19 
4 D 50.00 14.00 
5 E 62.50 17.50 
5.3.1 Knowledge depreciation prevention 
Interview with the biotech companies under study revealed that all companies consider 
knowledge continuity as important factor for a company to be in line with exponential growth of 
biotech sector but they lack specific knowledge management strategy. All companies use 
documentation and non-disclosure agreement as a tool for preventing knowledge depreciation. 
However, codification and human resource retention strategies were also adapted by Company 
B.  
Uncertainty of research output, individual accessibility of research output, long R&D and 
unpredictability of market performance of products makes the biotech R&D unique. Thus, 
retention of key human resources is most essential factor, which has been overlooked by 
companies under study with an exception of Company B. Thus, all companies should have HR 
retention strategy in order to maximize their human capital.  
All companies have either continuous and stable, or linear R&D expenditure pattern which is 
essential for preventing the knowledge depreciation. Early stage company, Company D, and 
younger companies in commercial stage (Company A and E) have 100% absorptive capacity in 
terms of R&D investment. Company B and C which are matured companies in commercial stage 
have their absorptive capacity of 10 and 15%, respectively. 
Biotech companies can use documentation, codification, NDA, HR retention strategy, article 
publication in journals, filing patent and patent application as tools to prevent knowledge 
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depreciation. In addition, regular internship program, workshop and training to the employees; 
and vertical integration of academia can leverage the effort preventing depreciation of 
knowledge.  
5.3.2 Motivation 
Challenging work environment was considered as an important motivating tool by Company B, 
C and E, whereas, Company A focuses on long term incentives as a primary motivating factor in 
addition to working environment, and Company C considers competent salary as a best 
motivating factor for their employees. It is obvious for Norway based Biotech Company to 
consider challenging work environment as a motivating tool because higher social security in 
Norway may inspire the employee for career development and higher achievement. Similar 
situations might not exist in other developing economies. In such situation, executive 
management should focus on other form of incentives. Furthermore, other form of incentives 
should also be taken into consideration during the internationalization of company because 
different environment demands different forms of motivation. This practice has been observed in 
Company A which focus on equity based long-term incentives in addition to competent salary 
and challenging work environment.  
Motivating factor differs from employee to employee. Traditionalists (born 1925-1945) prefer 
respect, self-identity and hierarchy. Job security, reward of hard work and stable work 
environment is preferred by Baby Boomers (born during post world war II, 1946-1964). 
Generation X (generation after baby boomers, 1965-1981) seeks higher salary, greater challenge 
and immediate feedback, where as skill development and new opportunity creation is the priority 
for generation Y (Mcallister & Vandlen, 2010). Genencor International and Genetech are 
considered to be role model biotech giants in their motivating and human resource retention 
practices because they have 8% turn over rate while the industry average is 20%. Genencor 
International focus on seminar, peer recognition, continuous educationa and professional 
development whereas Genentech practizes promotion, internal transfer and after tax check 
provision. In addition, Genentech has gLife program which provides the knowledge about 
different types of incentive pattern (Mcallister & Vandlen, 2010). Thus, these examples can 
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provide a valuable reference for biotech companies under study to adapt better strategy to 
prevent decay of knowledge. 
5.3.3 Knowledge generation 
All companies in this study are adopting learning by searching approach for knowledge 
generation. However, poor practice of learning by doing approach was observed in companies 
under study. Learning by doing approach of knowledge generation is essential for every 
company to enhance their competitive advantage. Techniques such as training, workshop, single 
loop learning, double loop learning, vertical integration of academia, public disclosure through 
patent, patent application/plant breeder’s rights, adapting talent development pool are some 
examples of learning by doing approach. Adopting learning by searching approach along with 
learning by doing approach can meet the goals of knowledge continuity and hence the human 
capital. 
5.4 Succession planning 
Leadership transition determines the degree of stability of a firm. The transition encounters more 
operational complexity as the firm size increases and greater will be the succession cost (Weber, 
1947). There occur more cost of while transferring firm specific knowledge to outsider. More 
error can occur in selecting human capital from outside and lost opportunity during outside 
recruitment and greater settlement time for outside successor result in higher succession cost. 
Thus, careful succession planning is essential for stability in firm performance. Succession 
planning also enhance the retention of top leadership human capital and can be the better 
motivation for other staffs as well  (Bulter & Roche-Tarry, 2002). 
Though none of the companies under study have a formal succession planning, they have 
indirectly implemented it through transition support during recruitment, coordination during 
point of inflection of product life cycle, talent development pool etc. The result shows that 
Company B has better succession planning with an overall score of 68.75% and poor succession 
planning of Company C with score of 34.38%. However, all of the company executives are 
reluctant about the CEO succession plan and none of them have identified their successors. 
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Table 5: Company wise effect of succession planning on hrf 
S. No. Company Indicator value Percentage contribution to hrf 
1 A 40.63 5.28 
2 B 68.75 8.94 
3 C 53.13 6.91 
4 D 56.25 7.31 
5 E 34.38 4.47 
Power issue, ego factor, personality contrast and more importantly feeling of self-dismissal lie 
behind succession planning which is a major obstacle in this process (Ogden & Wood, 2008). 
This was found to be true among most of the company studied. Non of the companies under 
study have their formal succession plan.  Their employees do not have knowledge about talent 
development pool. Furthermore, CEO from Company E retariated;  “there are a tones of CV 
coming daily to our company. So there is no need of preparation for successor in each 
department”. In addition, CEO added; “we are still in growth phase and existing manpower is 
sufficient to handle every circumstances”. In  this way, the executive from Company E showed 
reluctance to succession planning. The case is quite different with Company B which was 
following a performance scorecard to evaluate the potential candidates for succession. 
Inside succession was observed in company D and E whereas other three have outside 
succession. For those companies having outside succession, it is necessary for them to establish 
the talent development pool in order to find the viable candidate for succession within the 
company. Internal succession provides motivation for senior staffs as it increases the possibility 
of promotion and also leverage the effort in key employee retention. Furthermore, practice of 
internal succession reduces the transition cost and expenditure on human resource becomes more 
fruitful through the expertise of experienced and well trained internal candidates. 
With an exception of Company E, all companies under study have strong board transition 
support to their incomming CEOs. Strong coordination between department also exists in these 
companies during point of inflection in product life cycle and leadership transition. Only 
Company B has a practice of talent development pool in form of trainee employee and only 
Company D has the succession expert in board. 
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Role of board becomes crucial in this issue. Citing an example of Ralston Purina CEO 
succession, (Naveen, 2006) has mentioned that the outgoing CEO William Stiritz was awarded 
an option equivalent of $16 million for finding his successor. Every company should learn the 
importance of succession planning from this outstanding example.  
Therefore, well-defined talent development pool, regular consultation from succession expert, 
strong transition support for incoming CEOs, proper coordination between departments during 
the point of inflection in product life cycle and leadership transition will definitely leverage the 
effort toward smooth transition during leadership succession. Both, the executives and the board 
should be actively involved with shared responsibility in the process of succession planning. As 
a consequence, succession planning will boosts the human capital of any organization which 
leads to enhanced market performance and firm value. 
5.5 HR interaction effect 
Translating bioscience research outputs to global marketable products requires a complex 
interplay of knowledge in the field of science, management and law. This is only possible for a 
cross-disciplinary team via teamwork, effective communication, collaborative culture, and active 
board management interaction. Change in anyone discipline will have an impact on firm 
performance. Thus, effective interaction of the diverse workforce is essential for higher 
productivity. 
Table 6: Effect of HR interaction on hrf 
S. No. Company Indicator value Percentage contribution to hrf 
1 A 77.50 5.43 
2 B 75.00 5.25 
3 C 60.00 4.20 
4 D 65.00 4.55 
5 E 87.50 6.13 
 
In this study, parameters such as team work, board management interaction, interdepartmental 
communication, collaborative R&D culture and work force diversity were used to measure the 
human resource interaction status of the companies under study. The questionnaire-based study 
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showed that the companies under study have good interaction effect. Company E has highest HR 
interaction effect scoring 87.5% followed by Company A (77.5%) and Company B (75) while 
Company C has the lowest HR interaction effect with 60%. 
All companies under study have good internal communication, strong board management 
interaction, and collaborative culture in R&D. Effective interdepartmental communication and 
strong board management interaction can withstand possible technology and market turbulence 
which in turn has positive impact on product quality (Menon, Jaworsky, & Kohli, 1997). This 
has been supported by findings from Yates, (2006) which states that effective communication 
helps companies to cherish market premium by 19.4% higher than their counterparts. 
Furthermore, organizational stability as a result of effective internal communication is also a 
competitive advvantage for those firms. 
Executives of all companies with an exception of Company D believe on teamwork, participation 
and consensus. Leadership believes in entrepreneurship, innovation and risk taking with an 
exception of company C where the leadership is neutral to this attribute. Companies under study 
are neutral to hierarchical company structure except company D. Greater the hierarchical 
structure with in a company less efficient will be the communication lower will be the 
interconnectedness and greater will be the departmental conflict. This results in lower product 
quality and ultimately leads to lower market value of the firm (Menon, Jaworsky, & Kohli, 
1997).  
Workforce diversity enhances creativity, higher innovativeness and greater success in marketing 
(Gupta, 2013). Further detailed study by York, McCarthy, & Arnold, (2009) has identified two 
levels of diversity viz., surface level diversity and deep level diversity. They refer surface level 
diversity to demographic and functional differences and deep level diversity to differences in 
personality, values and attitude. By performing naturally occurring experiment on workforce 
diversity focused on bioscience enterprises, they found that surface level diversity enhances has 
positive impact on creativity and innovativeness, whereas deep level diversity tend to increase 
conflict. In this study very good surface level diversity was observed in Company A, good level 
of diversity in Company B and C, and fair in Company D and E. Poor deep level diversity was 
observed in Company E, good in A, B and C whereas Company D has very good deep level 
diversity. 
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Human resource interaction can be made effective in interdisciplinary firms like biotech firms by 
the practice of less hierarchical organizational structure with organic culture and team work 
where management is characterized by entrepreneurial, innovative and risk taking. In addition, 
active board-management interaction and effective interdepartmental communication will lead to 
economically positive impact of human resource in firm performance. Finally, maximizing the 
surface level diversity with minimum deep level diversity within the workforce will enhances the 
strength of intra-firm human capital. 
5.6 CEO effect 
CEOs perceive the organizational challenges and opportunities based on their mental orientations 
also known as “Conception of Control” in terms of Fligstein (Fligstein, 1987). This mental 
orientation or cognitive behavior is an outcome of CEO education and experience. This is often 
considered as the measure of quality of managers. Individuals with higher quality provide higher 
human capital to the firm which helps in better performance and thus, higher quality CEOs are 
the source of competitive advantage to the firm (Hitt, Bierman, Shimizu, & Kochhar, 2001).  
Furthermore, conversion of firm potential to actual market value is often determined by 
translational efficiency of total management team, especially the CEOs. This translational 
efficiency is often considered as an outcome of qualification and experience. 
Based on various parameters related to education and experience the CEO effect was determined. 
Highest CEO effect was observed in company B and lowest in Company D. 
Table 7: CEO effect on hrf 
S. No. Company Indicator value Percentage contribution to hrf 
1 A 70.00 21.00 
2 B 77.50 23.25 
3 C 60.00 18.00 
4 D 47.50 14.25 
5 E 67.50 20.25 
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For determining the quality of CEO; experience, education, level of education, type of education, 
and the university from which CEO is graduated were considered as the parameters. Early stage 
company, Company D has scientist as manager with doctorate degree in life science where as 
other companies in commercial phases were under the leadership of managers with masters 
degree in management related subject. There has been observed a special trend in CEOs 
educational background over time. Fligstein (1987), in his study of top leadership found that 
CEOs with manufacturing and operation background were dominant before 1930s. Period 
between 1930-1950 was dominated by CEOs with sales and marketing background and then 
finance in 1970s. In 1980s it has been observed the dominance of CEOs with operations and 
technical background (Wernerfelt, 1984), followed by MBA degree holders CEOs with the 
advent of 21
st
 century (Rakhmayil & Yuce, 2013). Figure 10 describes the trends of MBA 
holders in managerial position and the firm performance measured interms of Tobin’sQ4. The 
current trends in biotehnology shows that CEOs in biotechnology firms have degree in science 
along with MBA degree or some kind of executive education (Shimasaki, 2009). Scientific 
educational background is considered to be important particularly in pharma, medical device and 
biotech industry because it helps the CEOs to evaluate the technology critically. Critical 
assessment of the technology may help to identify and evaluate the threats and opportunity of the 
technology (Castanias & Helfat, 2001); (Cooper, Gimeno, & Woo, 1994). More competent 
evaluation of proposals was observed with CEOs having scientific educational background than 
CEOs without scientific educational background (Hitt, Bierman, Shimizu, & Kochhar, 2001). 
With common scientific appraoch the CEO and directors in board can easily accept and welcome 
the ideas which lead to productive collaboration between board and management team. This 
productive collaboration lead to better firm performance, seamless IPO transition and lower the 
underpricing during IPO (Finkelstein, Hambrick, & Cannella, 2009). However, the present trends 
in CEO educational background was observed poor in the company studied.  
                                                 
4
 Tobin’Q is defined as; Tobin’s Q = (Market value of equity – book value of equity + total assets)/Total assets) 
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Figure 10: Tobin's Q for companies over 30 year period with MBAs and without MBAs in management 
team.  Source: (Rakhmayil & Yuce, 2013) 
The quality of education obtained by CEOs also depends on ranking of the university from 
which the degree is obtained which in turn determine the firm performance. (Bhagat, Bolton, & 
Subramanian, 2010); (Rakhmayil & Yuce, 2013). In our study CEO from Company A, was 
found to have university degree from “Top 100 Universities” based on Times Ranking of 
University 2014 (Times Higher Education, 2014). Thus, Company A will have an advantage of 
having CEOs with better educational background and thus better performance. 
Hierarchy of skills is developed in upper echelons due to education and experiences. These skills 
may be industry specific, which can apply across industry or firm specific which helps in 
thorough understanding of the particular type of firm’s dynamics such as operations, culture and 
values, opportunity and vulnerabilities, social-cultural environment etc. (Castanias & Helfat, 
2001). Thus, experience of CEOs is considered as the most valuable human capital in biotech 
firms. Experience in public company boards is helpful for biotech company CEOs during their 
IPO performance. Similarly, start up experience and industry specific experience is significantly 
important in industry with exponential growth and knowledge intensive industry such as 
biotechnology industry. Industry specific experience of CEOs helps in prudent investment 
decision and also in competitive positioning of firm in that industry. Furthermore, international 
experience of total management team and diverse experience of board members reduces the 
cultural distance internationally and positively moderate the firm performance (Hutzschenreuter 
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& Horstkotte, 2013). The CEOs and total management team of company studied have high 
experience in managerial position, good international experience of total management team 
which thus adds positive value to CEO effect and finally to the human capital of firm. Poor start 
up success experience was observed in CEOs of company C and D and no biotech company 
experience was observed in CEO of Company C. 
In summary, highly qualified CEOs having scientific education along with managerial 
qualification from highly reputed universities; well experienced CEOs with international 
experience, startup success experience, and biotech company experience; and management board 
with diverged experience can provide better leadership for a biotech company.  
5.7 Summary of data modeling the human resource factor 
IP assets and relational capital collectively reflect the market potential of a biotech company. As 
proposed in the hypothesis, the translation of firm’s market potential to actual market value is 
determined by the human resources of a company. In this thesis, the translational efficiency of 
human resource is expressed in terms of human resource factor. Six human resource indicators 
viz. breed of managers, star scientists, knowledge continuity, succession planning, HR 
interaction, and CEO effect determine the human resource factor. The relation between human 
resource factor and its indicators can be expressed by using the formula proposed above in 
Chapter 3 and Chapter 4. 
= X1 V1 + X2V2 +………+ X6 V6, 
Or, 
= 15% V1 + 7% V2 + 28% V3 +13% V4 + 7%V5 + 30% V6 
Where, ‘’ is the measure of human resource factor (hrf). 
A pilot scale study on human resource factor of five Norwegian biotech companies revealed the 
results as shown in Table 8. Result indicates that Company B has highest hrf value of 77.87% 
followed by Company E, A and C, whereas, Company D has lowest hrf value of 59.78%. Thus, 
Company B has better human resource to translate its market potential to real market values than 
other companies studied.  
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Table 8: Human resource factor of companies under study 
S. No. Company Human Resource Factor (in percentage) 
1 A 66.80 
2 B 77.87 
3 C 63.79 
4 D 59.78 
5 E 68.30 
 
Finally, the model developed in this thesis can be widely used for the assessment of intra-firm 
human capital of biotech companies in terms of hrf. Accurate assessment of intra-firm human 
capital will provide information regarding the firm’s capacity to exploit its structural capital (IP 
assets and relational capital) and convert it into real market value. Thus, it adds simplicity and 
accuracy to existing life science valuation models. 
5.8 Limitations and criticism to the proposed model 
Limitations occur during the course of study, and are not under the control of researcher. 
Sometimes limitation affects the result and hence false conclusions are drawn. Although very 
few researches have been performed and much remains to be accomplished in life science 
valuation models, this study provides some preliminary insight on incorporating the human 
capital in biotech company valuations. However, this study is not without limitations. Some of 
the criticisms of the study focused on the model are discussed below. 
5.8.1 Indicators of human capital 
The six indicators of human capital that determine the human resource factor of the valuation 
model are proposed theoretically based on the available literatures. It cannot be fully assured that 
these indicators represent all aspects of internal human capital of biotech firms. Large scale 
survey on individual components of biotech firm’s human capital should be conducted in order 
to verify their significance. Large scale survey is beyond the scope of this master’s thesis project. 
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5.8.2 Linear and constrained model 
Simple and linear model was proposed to determine the translational efficiency of human capital. 
Thus, human resource factor (hrf) varies linearly according to variation in its various indicators 
(breed of managers, star scientists, knowledge continuity, succession planning, HR interaction, 
and CEO effect). The linear relation may not always exist in reality. For example, interaction 
between the individual components of hrf can have synergistic effect or antagonistic effect on 
hrf. This possibility of inter-linkage between individual parameters has been ignored in the 
model proposed in this study. A more complex and exponential model defining the inter linkage 
between these individual components could be an improved solution. However, exponential 
modeling that requires the expertise on econometrics is beyond the scope of this study. 
Specific weight is assigned to all six indicators of hrf. Assignment of weight is based on 
available literatures from similar subjects. The possible variation of assigned weight of each 
indicator is not explained properly. Furthermore, breed of managers is a new indicator proposed 
in this study and assigning weight to this indicator is a supposition which may not hold true. 
Thus, the task of assigning weight to each indicator should be performed by obtaining 
statistically significant data. 
5.8.3 Data and statistical significance 
Human capital, being a source of competitive advantage, is often considered confidential. 
Retrieving confidential data via mailed questionnaire is irrelevant because of high probability of 
very low response rates.  Thus, a questionnaire-based interview was performed with executives 
of five biotech companies to obtain the relevant data. Descriptive analysis of human capital was 
performed. Statistical validation of the model with real life data however remained unsolved due 
the limitation in data set. It would have been possible for professional service providers or 
research institutes to conduct myriad of interviews to obtain large data sets which could prove 
the statistical significance of the proposed model. However, this practice is irrelevant for 
master’s thesis due to limitations in time and scope. 
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5.8.4 Sensitivity analysis 
Sensitivity analysis studies the uncertainty in output that results from the uncertainty associated 
with input parameters in a mathematical system, equation or model (Saltelli, et al., 2008).  
Assumptions made on input parameters are subject to change.  Small change in these parameters 
may result in change in output. This can have impact in the conclusion drawn from the models. 
Thus, sensitivity analysis is a simpler technique for impact assessment of input parameter to the 
output in mathematical system. 
 In this study, sensitivity analysis of Company A was carried out to demonstrate how the 
uncertainty associated with input parameters (breed of managers, star scientists, knowledge 
continuity, succession planning, HR interaction and CEO effect) impact on the output (human 
resource factor). Here, each parameter was changed by 20% in both direction while keeping all 
other variables constant and its impact on hrf was observed. The following Figure 11 illustrates 
the impact assessment through sensitivity analysis.  
 
Figure 11: Sensitivity analysis for company A 
The sensitivity analysis graph shows that with the change in one input parameter by 20%, while 
other parameters remaining constant, hrf changes accordingly. However the change observed is 
not uniform. This variable change indicates that the input parameters have different impact on 
hrf.  As observed in Figure 11, CEO effect has more impact followed by knowledge continuity 
where as star scientist effect has the least impact on hrf followed by succession planning. 
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6 CONCLUSION AND RECOMMENDATIONS 
6.1 Conclusion 
Valuation in life science has a long history from measure of lab footage to present day valuation 
based on return on investment. Review of literatures revealed that human capital was most 
important component that determines the firm value. However, it has been found to be either 
missing or improperly incorporated in valuation models. This study properly introduces the role 
of human capital in life science valuation practice through the introduction of human resource 
factor (hrf). The human resource factor, which determines the translational efficiency of  firms 
market potential to actual market value, is an outcome of human capital related parameters viz., 
breed of managers, star scientists, knowledge continuity, succession planning, human resource 
interaction and finally the CEO effect. 
All six human capital related parameters for companies under this study were estimated through 
the analysis of results obtained from questionnaire-based interviews. All companies follow the 
stage specific management and thus the corresponding value of the parameter, breed of 
managers, was found to be 100% to all companies under study. Average star scientist effect for 
five companies under study was 66.56% where, company B has the highest star scientist effect of 
83.8% and company D has the lowest, 50%. Similarly, the questionnaire based survey showed 
that the knowledge continuity practice was found to be highest for company B followed by E, C, 
A and D accounting 69.89%, 62.50%, 57.81%, 56.25% and 50% respectively. Almost all 
companies under study were reluctant to succession planning. The study also revealed that 
average succession planning for five companies was 50.62%. Company B has better succession 
planning (68.75%) as compared to other companies under study while Company E has the 
weakest succession planning (34.38%). Human resource interaction effect for all five companies 
was better than all the indicators of human resource factor with an average of 73.01% with 
highest value for company E (87.50%) and lowest for company C (60%). All companies under 
study have well qualified and experienced CEOs. Examining the different aspect of CEOs 
revealed the average CEO effect of 64.5% with lower value for company D (47.5%) and highest 
for company B (77.5. It was also found that Company B has better star scientist effect, 
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knowledge continuity practice, succession planning and CEO effect as compared to other 
companies under study. Similarly, company E has the best human resource interaction among the 
five companies under study. 
Human resource factor was computed by inserting the parameters value on proposed equation. 
This revealed that company B has highest hrf value of 77.87% followed by Company E 
(68.30%), company A (66.80%), company C (63.79%) while company D has lowest hrf value 
(59.78%). The hrf value indicates that company B has highest translational efficiency as 
compared to other companies and thus it can efficiently translate its market potential to market 
value. Furthermore, sensitivity analysis for Company A reveals that the proposed model is more 
sensitive to CEO effect and least to succession planning.  
Finally and most importantly, the data supports that successful estimation of intra firm human 
capital by the proposed model can be advantageous in determining the translational efficiency of 
the human resource within the firm. And, efficient translation of market potential to market value 
results in higher market value of firm. 
6.2 Recommendations 
1) A theoretical approach in assigning weight to different indicators of hrf was adopted in 
this study. A statistical approach containing a much larger and significant data set is 
beyond the scope of the study due to the limited time period for master’s thesis, and 
confidential nature of data sets used in measuring human capital. Therefore, a statistical 
approach containing a much larger and significant data set could be used to define the hrf 
factor. 
2) Vast array of literature is available for each parameter in industries other than biotech 
industry. Therefore, detail study of each parameter could be helpful in developing a 
human resource scorecard in biotechnology industry. Scorecard developed in this manner 
could be used in measuring the translational efficiency of the biotech firms. 
3) This study is based on a pilot scale study including only five biotech companies 
representing mostly the blue green biotech sector. Detailed and large-scale study on 
individual field of biotech (blue, green, white, red) could contribute in developing 
specific human resource factor for each sector of biotechnology. Estimation of human 
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capital in terms of human resource factor could determine the translation efficiency. By 
having the knowledge of human capital; negotiation related to merger and acquisition, 
investment decisions, licensing, fundraising activities etc., will become relatively simpler. 
4) Introducing the best practice of each parameter; breed of managers, star consulting 
scientists, knowledge continuity practices, succession planning, best HR interaction and 
higher quality CEOs; could enhance the human capital of biotech firms and finally the 
firms’ market value. 
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APPENDIX  
List of Questionnaires 
A. Breed of Managers: 
Please answer the next questions with a score 1-5 where 5 is the best  
1. How many products are in the market? 
1 2 3 4 5 
0 1-5 6-10 10-15 >15 
2. How many Products are in product development pipeline? 
1 2 3 4 5 
0 1-5 6-10 10-15 >15 
3. Academic qualification of CEO (choose among the following options) 
Science MBA Finance Law Accounting Marketing Other/specify 
       
4. Academic qualification of Past CEO during start up phase (if any) 
Science MBA Finance Law Accounting Marketing Other/specify 
       
5. How many numbers of Divisions/ Department are there in your company? (Please name 
them). 
 
6. Please mention the academic qualification of managers leading each department/ 
Division. 
 
7. Do you follow the Stage Specific Management5? 
                                                 
5
 Stage Specific Management: 
Early Stage innovation better managed by Scientists 
Later stage of clinical trials (or later stage of field trials in blue green biotech) and regulatory approvals 
market development and IPO by Marketing Managers 
Commercial stage production and market regulation by managers  
 78 
 
0 1 
No Yes 
8. If you do not have stage specific management practice which alternative strategy you 
think would better fit in biotechnology industry? 
B. Star Scientists 
9. How many Scientific Staffs are involved in research and development? 
 
10. Are the R & D staffs allowed to publish their research in Journal Publications? 
0 1  
No Yes 
11. How often they publish their research articles in renowned international journal 
publications? 
1 2 3 4 5 
Never Rarely Occasionally Frequently Very Frequently 
12. Is there a collaboration of firm scientists with academic stars (Academic 
scientists/Professors in University)? 
0 1 
No Yes 
Please answer the questions with score 1-5 where 5 is the best 
13. The number of articles co-authored by firm scientists with academic stars 
1 2 3 4 5 
1-5 6-10 11-15 16-20 >20 
14. Is there a presence of Scientists in Board of Directors/ venture capitalist? 
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0 1 
No Yes 
15. What types of Scientific Staffs are involved in your firm? 
Firm Employee 
Scientist/ Employee 
researcher 
Star Scientists/ 
Academic Scientist 
Consulting Scientist Star Consulting 
Scientist 
    
C. Knowledge depreciation prevention strategy/knowledge continuity 
Please answer the questions with score 1-5 where 5 is the best 
16. How important is knowledge continuity for Company ____ to be in line with exponential 
growth of Biotech sector? 
1 2 3 4 5 
Unimportant Of little 
importance 
Moderately 
important 
Important Very important 
17. How often the company uses the following techniques for knowledge continuity for a 
company to be updated with the exponential growth of biotech sectors? 
S. 
No. 
Knowledge generating techniques Always Very 
Often 
Sometimes Rarely Never 
1 Public disclosure through article      
2 Public disclosure through patent and 
patent application 
     
3 Internship      
4 Interaction with academia (vertical      
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integration of academia) 
5 Seminar/training workshop/ 
conference 
     
6 Lower loop learning/ lower level 
learning 
     
7 Double Loop Learning/ Higher level 
learning 
     
8 Talent Development Pool      
 
18. How often you use the following parameters for preventing the knowledge depreciation? 
S. 
No. 
Knowledge Depreciation Prevention 
Strategy 
Always Very 
Often 
Sometimes Rarely Never 
1 Documentation      
2 Codification      
3 NDA agreement       
4 Human capital retention      
19. What is the key human resource retention strategies/Motivation Techniques adopted 
mostly? 
S. 
No. 
Motivation techniques Always Very 
Often 
Sometimes Rarely Never 
1 Long term incentives/ stock options/ 
equity option 
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2 Attractive salary      
3 Bonus payment      
4 Other type of incentives/ (specify)      
20. What is the R& D expenditure pattern adopted in your company? 
S. 
No. 
Expenditure pattern Always Very 
Often 
Sometimes Rarely Never 
1 Continuous and stable      
2 Linear      
3 Exponential      
4 Funding with boom and boost cycle 
depending on the nature of research 
     
21. The absorptive capacity of a firm (% of total revenue used for R and D . if the company 
do not generate revenue, the r and D intensity or the absorptive capacity is considered to 
be 100% ) 
_____________ 
D. Succession Planning   
22. How long have you been in the Office as a CEO? (In Years) 
 
23. How long did the former CEO serve the company before you were recruited? (In Years) 
 
Please answer the following questions with score 0 or 1 for No or Yes respectively 
24. Have you served in any other position in this present company before being selected as a 
CEO? 
0 1 
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No Yes 
25. As a CEO, do you have a written document detailing the Skills required for next 
successors in each department of your company? 
0 1 
No Yes 
26. Do your employees know about the formal talent development Pool? 
0 1 
No Yes 
27. In each department, do you have viable candidate for succession? 
0 1 
No Yes 
28. Does the Board has succession expert / research consultant to advice for succession? 
0 1 
No Yes 
The following items are measured in 5 points Likert scale, Please answer the following 
questions with a score 1-5, where 5 is the best. 
29. When you were recruited as a CEO, are you provided with on board/transition support? 
1 2 3 4 5 
Never Rarely Occasionally Frequently Very Frequently 
30. How you grade the coordination that exist in your company during the point of inflection 
in product life cycle and leadership transition 
1 2 3 4 5 
Very weak Weak Satisfactory Strong  Very Strong 
31. How would you rate the overall succession planning of your company? 
1 2 3 4 5 
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Poor  Fair  Good  Very Good  Excellent 
E. Human resource interaction effect 
The following items are measured in 5 points Likert scale, Please answer the questions 
with score 1-5 where 5 is the best 
32. The culture within Biotech Company ___________ is characterized by team work 
participation and consensus 
1 2 3 4 5 
Strongly 
disagree 
Disagree Neutral Agree Strongly agree 
33. The culture within Biotech Company ___________is very controlled and structure place 
formal procedure generally govern what people do 
1 2 3 4 5 
Strongly 
disagree 
Disagree Neutral Agree Strongly agree 
34. The leadership exemplify entrepreneurship, innovation, or risk taking 
1 2 3 4 5 
Strongly 
disagree 
Disagree Neutral Agree Strongly agree 
35. Surface level diversity* observed in your firm  
1 2 3 4 5 
Poor  Fair  Good  Very Good  Excellent 
* Surface level diversity: Observed difference among the team members on demographic 
basis; for example; age, race, gender, national culture and ethnicity, as well as differences 
along disciplinary or functional background. 
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36. Deep Level Diversity* observed in your Firm 
1 2 3 4 5 
Poor  Fair  Good  Very Good  Excellent 
*Deep Level Diversity: Observed difference among the team members on personalities, 
values and attitude 
37. Collaborative cultures in R & D  
1 2 3 4 5 
Poor  Fair  Good  Very Good  Excellent 
38. Company preference to interdepartmental communication via face to face meeting 
1 2 3 4 5 
Poor  Fair  Good  Very Good  Excellent 
39. Company preference to interdepartmental communication via electronic means 
1 2 3 4 5 
Poor  Fair  Good  Very Good  Excellent 
     
40. How would you explain Board-Management interaction within your company 
1 2 3 4 5 
Poor  Fair  Good  Very Good  Excellent 
     
41. Company is a member of some scientific research cluster 
0 1 
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No Yes 
F. CEO Effect 
Conversion of firm potential to actual market value is often determined by translational 
efficiency of total management team, especially the CEOs.  This translation efficiency is 
often considered as an outcome of qualification and experience. 
Please choose one of the following 
42. CEO of Company _____ has the following academic qualification 
MBA Degree Economic 
Degree* 
Technical 
Education 
Others (Specify) 
    
* Degree in Economics/Finance/Accounting/Marketing etc 
43. Level of Academic qualification attained by the CEO 
PhD Masters Bachelors Other (Specify) 
    
44. What is the name of the academic institute from which the CEO is graduated? 
Please answer the next questions with a score 1-5 where 5 is the best  
45.  Past Experience as a CEO  
1 
 
2 3 4 5 
No Low Average  High Very high 
46. Present CEO experience  in any managerial position before  
1 2 3 4 5 
No Low Average  High Very high 
 86 
 
47. Past experience of present CEO as manager/ CEO in the field of biotechnology 
1 2 3 4 5 
No Low Average  High Very high 
48. Past experience of CEO as CEO and Board of Directors  
1 2 3 4 5 
No Low Average  High Very high 
49. International experience of total management team (TMT)/ CEO by being born abroad, 
studied abroad or Worked Broad 
1 2 3 4 5 
No Low Average  High Very high 
50. Past start up success experience of CEO 
1 2 3 4 5 
No Low Average  High Very high 
51. Diversity of experience in board of directors  
1 2 3 4 5 
No Low Average  High Very high 
THANK YOU 
